Home » Stocks » Aditx Therapeutics

Aditx Therapeutics, Inc. (ADTX)

Stock Price: $3.20 USD -0.42 (-11.60%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
After-hours: $3.35 +0.15 (4.69%) Jul 10, 6:48 PM

Stock Price Chart

Key Info

Market Cap 12.63M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 5.17M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $3.20
Previous Close $3.62
Change ($) -0.42
Change (%) -11.60%
Day's Open 3.62
Day's Range 3.17 - 3.70
Day's Volume 176,734
52-Week Range 3.17 - 7.08

More Stats

Market Cap 12.63M
Enterprise Value 13.25M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 5.17M
Float 1.94M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash -618,634
Net Cash / Share -0.16
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue--
Operating Income-5.87-5.61
Net Income-5.83-5.69
Shares Outstanding3.833.63
Earnings Per Share-1.52-1.57
Operating Cash Flow-0.46-0.39
Free Cash Flow-0.46-0.39
Cash & Equivalents0.000.12
Total Debt0.170.16
Net Cash / Debt-0.16-0.05
Assets0.120.12
Liabilities2.981.65
Book Value-2.85-1.54
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aditx Therapeutics, Inc.
Country United States
Employees 2
CEO Amro Albanna

Stock Information

Ticker Symbol ADTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADTX
IPO Date June 30, 2020

Description

ADiTx Therapeutics, Inc., a life sciences company, focuses on developing nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients and address autoimmune diseases and allergies. The company commercializes Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. It also develops ADi products for organ transplantation, skin grafting, autoimmune diseases, allergies, and other applications. The company has a license agreement with Loma Linda University. ADiTx Therapeutics, Inc. was founded in 2017 and is headquartered in Loma Linda, California.